Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
RXST · against 217 other Healthcare companies of similar size
Ranked #108 of 218 · scores higher than 39% of peers
Bars: peers in each 10-point band of the valuation score40 peers with a valuation score of 30–39, including RXST · Click a bar to see the companies
Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | RXST | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 202 reported | -24.8% | -2.1% | 27% | 30% | |
| EBITDA yieldHigher is better · 224 reported | -30446.7% | 1.6% | 0% | 50% | |
| Free cash flow yieldHigher is better · 133 reported | -14.2% | -12.1% | 47% | 20% | |
| Book yieldHigher is better · 207 reported | 138.0% | 62.6% | 83% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 108 | 110M USD | 33 | 54 | |
| 108 | 117M USD | 33 | 40 | |
| 108 | 276M USD | 33 | 46 | |
| 108 | 149M USD | 33 | ||
| 108 | 191M USD | 33 | 38 | |
| 108 | 165M USD | 33 | 50 | |
| 108 | 158M USD | 33 | 14 | |
| 108 | 142M USD | 33 | 45 | |
| 108 | 184M USD | 33 | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score